Pfizer will report earnings on Tuesday before the market open. The FMHR traders debate the bull and the bear case for the stock. Barbara Ryan, FTI Strategic Communications, shares her recommendations for investing in pharma stocks now.
LONDON (Reuters) - Pfizer suffered a second rejection in two days from Britain's health cost watchdog NICE as its new kidney cancer drug Inlyta was turned down for use on the state health service. Full story
CNBC's Brian Shactman reports 8 Dow components hit new highs today including Pfizer; and Don Luskin, Trend Macro and Jim LaCamp, UBS, discuss how Wall Street is reacting to the debt debate, and where stocks go from here.
The entrance of Pfizer World headquaters in New York City, August 31, 2003. ECONM REUTERS/Jeff Christensen JC